Table 1. Baseline characteristics.
| Standard chemotherapy (n=337) | Standard chemotherapy plus bevacizumab (n=337) | |
|---|---|---|
| Age (years) | ||
|
| ||
| Median (IQR) | 60·6 (53·6-67·7) | 59·5 (53·6-66·4) |
| Range | 23–85 | 26–84 |
|
| ||
| Race | ||
|
| ||
| American Indian | 1 (<1%) | 4 (1%) |
| Asian | 44 (13%) | 48 (14%) |
| African American | 15 (4%) | 15 (4%) |
| Native Hawaiian/Pacific islander | 0 | 1 (<1%) |
| White | 271 (80%) | 266 (79%) |
| Missing/unknown | 6 (2%) | 3 (1%) |
|
| ||
| Stage | ||
|
| ||
| I | 17 (5%) | 22 (7%) |
| II | 36 (11%) | 18 (5%) |
| III | 246 (73%) | 261 (77%) |
| IV | 38 (11%) | 36 (11%) |
|
| ||
| Histology | ||
|
| ||
| Serous* | 272 (81%) | 273 (81%) |
| Endometrioid | 23 (7%) | 20 (6%) |
| Clear cell | 14 (4%) | 10 (3%) |
| Mucinous | 2 (1%) | 2 (1%) |
| Other† | 26 (8%) | 32 (9%) |
|
| ||
| Grade of differentiation | ||
|
| ||
| Well | 17 (5%) | 20 (6%) |
| Moderate | 44 (13%) | 53 (16%) |
| High | 253 (75%) | 249 (74%) |
| Not available | 22 (7%) | 15 (4%) |
|
| ||
| Cytoreductive surgery‡ | ||
|
| ||
| Randomised, no surgery | 27 (8%) | 27 (8%) |
| Randomised, surgery | 27 (8%) | 26 (8%) |
| Not randomised | 283 (84%) | 284 (84%) |
|
| ||
| Previous treatment-free interval§ | ||
|
| ||
| 6–12 months | 105 (31%) | 105 (31%) |
| >12 months | 232 (69%) | 232 (69%) |
|
| ||
| Previous platinum-free interval ¶ | ||
|
| ||
| 6–12 months | 84 (25%) | 91 (27%) |
| >12 months | 253 (75%) | 246 (73) |
|
| ||
| Measurable disease | ||
|
| ||
| No | 50 (15%) | 63 (19%) |
| Yes | 287 (85%) | 274 (81%) |
|
| ||
| Previous therapies | ||
|
| ||
| Systemic chemotherapy | ||
| Yes | 337 (100%) | 337 (100%) |
| No | 0 | 0 |
| Intraperitoneal chemotherapy | ||
| Yes | 66 (20%) | 55 (16%) |
| No | 271 (80%) | 282 (84%) |
| Hormonal therapy | ||
| Yes | 10 (3%) | 11 (3%) |
| No | 327 (97%) | 326 (97%) |
| Anti-VEGF or bevacizumab | ||
| Yes | 33 (10%) | 34 (10%) |
| No | 303 (90%) | 303 (90%) |
| Not specified | 1 (<1%) | 0 |
|
| ||
| First-line maintenance therapies | ||
|
| ||
| Taxane | ||
| Yes | 27 (8%) | 20 (6%) |
| No | 310 (92%) | 317 (94%) |
| Bevacizumab | ||
| Yes | 22 (7%) | 14 (4%) |
| No | 315 (93%) | 323 (96%) |
| Other | ||
| Yes | 2 (1%) | 4 (1%) |
| No | 335 (99%) | 333 (99%) |
Data are n (%) unless stated otherwise.
*
Low-grade serous cancer was not excluded but was not specifically defined in this trial.
†
Other includes adenocarcinoma, not otherwise specified.
‡
Stratification variable.
§
Treatment-free interval reported here is data submitted immediately before randomisation and not data recorded in the electronic case-report forms.
¶
Variable as reported on the electronic case-report forms.